Document Detail


Biomarkers in advanced larynx cancer.
MedLine Citation:
PMID:  23775802     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVES/HYPOTHESIS: To determine if tumor biomarkers were predictive of outcome in a prospective cohort of patients with advanced larynx cancer treated in a phase II clinical trial.
STUDY DESIGN: Prospectively collected biopsy specimens from 58 patients entered into a Phase II trial of organ preservation in advanced laryngeal cancer were evaluated for expression of a large panel of biomarkers, and correlations with outcome were determined.
METHODS: Tissue microarrays were constructed from pretreatment biopsies and stained for cyclin D1, CD24, EGFR, MDM2, PCNA, p53, survivin, Bcl-xL, Bcl-2, BAK, rhoC, and NFκB. Pattern of invasion and p53 mutations were assessed. Correlations with overall survival (OS), disease-specific survival (DSS), time free from indication of surgery, induction chemotherapy response, and chemoradiation response were determined. Cox models were used to assess combinations of these biomarkers.
RESULTS: Low expression of BAK was associated with response to induction chemotherapy. Low expression of BAK and cytoplasmic NFκB was associated with chemoradiation response. Aggressive histologic growth pattern was associated with response induction chemotherapy. Expression of cyclin D1 was predictive of overall and disease-specific survival. Overexpression of EGFR was also associated with an increased risk of death from disease. Bcl-xL expression increased significantly in persistent/recurrent tumors specimens when compared to pretreatment specimens derived from the same patient (P = 0.0003).
CONCLUSIONS: Evaluation of biomarker expression in pretreatment biopsy specimens can lend important predictive and prognostic information for patients with advanced larynx cancer.
Authors:
Carol R Bradford; Bhavna Kumar; Emily Bellile; Julia Lee; Jeremy Taylor; Nisha D'Silva; Kitrina Cordell; Celina Kleer; Robbi Kupfer; Pawan Kumar; Susan Urba; Francis Worden; Avraham Eisbruch; Gregory T Wolf; Theodoros N Teknos; Mark E P Prince; Douglas B Chepeha; Norman D Hogikyan; Jeffrey S Moyer; Thomas E Carey
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural     Date:  2013-07-12
Journal Detail:
Title:  The Laryngoscope     Volume:  124     ISSN:  1531-4995     ISO Abbreviation:  Laryngoscope     Publication Date:  2014 Jan 
Date Detail:
Created Date:  2013-12-30     Completed Date:  2014-03-10     Revised Date:  2014-08-10    
Medline Journal Info:
Nlm Unique ID:  8607378     Medline TA:  Laryngoscope     Country:  United States    
Other Details:
Languages:  eng     Pagination:  179-87     Citation Subset:  IM    
Copyright Information:
© 2013 The American Laryngological, Rhinological and Otological Society, Inc.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Humans
Laryngeal Neoplasms / chemistry*,  mortality,  pathology,  therapy
Middle Aged
Neoplasm Staging
Prognosis
Prospective Studies
Survival Rate
Treatment Outcome
Tumor Markers, Biological / analysis*
Grant Support
ID/Acronym/Agency:
P30 CA046592/CA/NCI NIH HHS; P30 CA46592/CA/NCI NIH HHS; P50 CA097248/CA/NCI NIH HHS; P50 CA97248/CA/NCI NIH HHS
Chemical
Reg. No./Substance:
0/Tumor Markers, Biological
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The effect of rising food prices on food consumption: systematic review with meta-regression.
Next Document:  Investigating the mutation resistance of non-nucleoside inhibitors of HIV-RT using multiple microsec...